AKT1 and Cognitive impairment: In scopolamine-treated mice, significant cognitive impairment was observed; while mouse locomotor activity was not affected, three behavior tests, including Y-Maze, novel object recognition, and MWM test, all consistently supported the improvement of learning and memory in mice by Tak supplement, accompanied by significantly increased neuronal Akt signaling and redox status.